AnodyneWiki

Minoxidil

Minoxidil
Minoxidil
Salts
[]
Minoxidil tartrate
Minoxidil tartrate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass209.25 g/mol [1]
Melting point248 °C [1]
Solubility2200 mg/L [1]
Predicted LogP1.2 [1]
Structural Identifiers
[]
Molecular formulaC9H15N5O
IUPAC name3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
SMILESC1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
InChIInChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
InChIKeyZIMGGGWCDYVHOY-UHFFFAOYSA-N
CAS number38304-91-5
UNII5965120SH1
PubChem CID4201
Pharmacokinetics[]
OnsetOral: 30–60 minutes (peak), Sublingual: 30 minutes
Elimination half-lifeOral: 3–4 hours, Topical: 22 hours[3]
Duration of actionOral: ~72 hours, Topical: 10–12 hours
MetabolismPrimarily liver via glucuronidation, hydroxylation, and sulfation (SULT1A1, SULT2A1)
ExcretionUrine: >97% (10–15% unchanged; within 12–20 hours for oral and 4 days for topical)
Routes of administrationOral, sublingual, topical (solution, foam, spray)

Minoxidil (also known as Loniten, Rogaine, Minoximen, Theroxidil, Alopexil, Alostil, Tricoxidil, Lonolox, Regaine or Normoxidil) is a calcium channel blocker substance of the piperidine class.

Chemistry

Salts []

Minoxidil is typically found in the form of its tartrate salt.

 []

Minoxidil is achiral.

Minoxidil matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Minoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl<sup>-</sup>2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target1
shared target1

Medical side effects []

38 side effects listed on drug labels in (minoxidil).

  • Angina pectoris
  • Breast disorder
  • Cardiac tamponade
  • Oedema
  • Toxic epidermal necrolysis
  • Dermatitis
  • Rash
  • Gastrointestinal disorder
  • Cardiac disorder
  • Hypertrichosis
  • Hypotension
  • Leukopenia
  • Mediastinal disorder
  • Nausea
  • Pericardial effusion
  • Pericarditis
  • Pleural effusion
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Tachycardia
  • Thrombocytopenia
  • Virilism
  • Vomiting
  • Weight increased
  • Oedema peripheral
  • Dermatitis bullous
  • Bullous eruption
  • Blood alkaline phosphatase increased
  • Malnutrition
  • Skin disorder
  • Hair growth abnormal
  • Breast tenderness
  • Fluid retention
  • Water retention
  • Electrocardiogram ST segment
  • Hair colour changes
  • Electrocardiogram abnormal
  • Blood creatinine increased

Indications

  • Cardiac output increased
  • Encephalopathy
  • Hypertension
  • Refractory hypertension
  • Retinal disorder
  • Vascular resistance systemic
  • Water retention

Subjective effects []

0xea / Minoxidil []
Routes:
  • Transdermal
  • Oral (10 - 15mg)
Indication:Effects:Notes:
  • seams to promote hair-regrowth

 []

  • Australia: Minoxidil is a S4 / S2.[4][5]
  • United Kingdom: Minoxidil is a GSL / Prescription only.[6][7][8]
  • United States: Minoxidil is a Topical OTC / Oral Prescription only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4201, Minoxidil. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4201
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Minoxidil. UNII: 5965120SH1. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5965120SH1
  3. Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. The Journal of Dermatological Treatment. June 2022; 33(4):1896–1906. PMID 34159872. https://doi.org/10.1080/09546634.2021.1945527
  4. 59445 WOMEN'S REGAINE EXTRA STRENGTH Minoxidil 5% application bottle. Therapeutic Goods Administration (TGA) / Australian Government Department of Health and Aged Care. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=59445&agid=%28PrintDetailsPublic%29&actionid=1
  5. Search the TGA website. Tga-search.clients.funnelback.com. https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=79914
  6. Loniten Tablets 5mg - Summary of Product Characteristics (SmPC). Medicines.org.uk. November 24, 2020. https://www.medicines.org.uk/emc/product/4296/smpc
  7. Regaine for Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam (GSL) - Summary of Product Characteristics (SmPC). (emc). April 27, 2021. https://www.medicines.org.uk/emc/product/5781/smpc
  8. Regaine for Women Once a Day Scalp Foam 5% w/w Cutaneous Foam - Summary of Product Characteristics (SmPC). Medicines.org.uk. October 28, 2020. https://www.medicines.org.uk/emc/product/5082/smpc

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 10:20:29
drugspromissing (no DrugsPRO reagent data)2026-11-20 10:20:25
erowidmissing (no Erowid substance of that name)2026-11-20 10:20:25
gsrsok2026-11-20 10:20:26
hmdbmissing (no HMDB id)2026-11-20 10:20:25
keggok2026-11-20 10:20:27
pubchemok2026-11-20 10:20:25
redditmissing (no r/tripreports posts mention it)2026-11-20 10:20:25
siderok2026-11-20 10:20:25
structureok2026-11-20 10:20:25
wikipediaok2026-11-20 10:20:25